HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) and raises the price target from $17.5 to $20.
March 11, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on ALX Oncology Holdings and raises the price target from $17.5 to $20.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100